ATTACK Trial results #ECCMID2022: efficacy & safety of sulbactam-durlobactam (SUL-DUR) vs colistin for Acinetobacter baumannii complex. Sulbactam has intrinsic activity against AB (PBP binding); durlobactam potent inhibition of class A, C,D beta-lactamases
pubmed.ncbi.nlm.nih.gov/28665414/ this was a phase 3 non-inferiority trial of HAP, VAP, BSI randomized 1:1 to SUL-DUR plus IMI or Colistin + IMI. primary efficacy outcome 28-day ACM, safety = nephrotoxicity measured by RIFLE #ECCMID2022

With the Jan 7th announcement of the @remap_cap IL-6ra results: medrxiv.org/content/10.110…

and last nights @BMJ_Latest RCT drop: bmj.com/content/372/bm…

let’s talk about tocilizumab [thread, 1/n] COI: I am the pharmacist lead for @remap_cap @UPMC, however, we didn’t enroll to the tocilizumab domain due to supply issues in the US—drug was reserved for RA and CAR T patients. I saw the data with the rest of the world the day the pre-print was posted. [2/n]

up bright and early to hear @IDpharmresearch, Dr. Jennifer Le, and Dr. Tom Lodise to go through the new #vancomycin guidelines at #ASHP19 @IDpharmresearch 61 years of vanco and "we are still not confident the best way to dose" #ASHP19

Antifungal Stewardship in Solid Organ Transplantation presented by @JGPharmD at #ACCPAM19 @JGPharmD hard to follow the CAP guidelines, but Dr. Gallagher starts with a nice overview of the kingdom myceteae #ACCPAM19

starting #ACCPAM19 with the amazing @emilylheil presenting an update on the recently-published community-acquired pneumonia #CAP guidelines ncbi.nlm.nih.gov/pubmed/31573350 @emilylheil So what actually causes CAP? @emilylheil states "the pathogenesis and etiology of CAP has changed over time with increased rates of vaccination and better diagnostics." Jain et al 2015 unable to identify a pathogen in > 60% of patients, viruses most common
ncbi.nlm.nih.gov/pubmed/26172429

my grandpa has been in the hospital for the past week w/ Acinetobacter baumannii bacteremia.

I keep deleting this, but I think I need to share what I learned about antibiotics and fear, and reinforce the life-saving nature of stewardship [thread] 1/ First, I just want to say my grandpa is the best human. From a tiny town in WV. He started the cable company back in the day bc "people deserved to know the news" Sold it for a song once it was established because he had achieved his goal. Help people, at no personal gain. 2/

Round 2 of the Great ID Debates of #ASHP18 @ASHPOfficial comes to us from the brilliant minds of @SIDPharm members @TimbrookTT and @julie_justo. To start us off, Tristan makes the case for #fidaxomicin (FID) for treatment of Clostridioides difficile (#cdiff) infection .@TimbrookTT sets up the major points for FID in the treatment of #Cdiff: 1- ⬇️recurrence compared to #vancomycin (VAN) in RCTs + ⬆️in cure without recurrence (aka global clinical cure) 2- this held up in real-world data 3- cost-effectiveness analyses support 1st line use #ASHP18